These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27499892)

  • 1. Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
    Cheon DJ; Walts AE; Beach JA; Lester J; Bomalaski JS; Walsh CS; Ruprecht Wiedemeyer W; Karlan BY; Orsulic S
    J Pathol Clin Res; 2015 Jan; 1(1):41-53. PubMed ID: 27499892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
    Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
    Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
    McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
    BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
    Gupta S; Sahu D; Bomalaski JS; Frank I; Boorjian SA; Thapa P; Cheville JC; Hansel DE
    Endocr Pathol; 2018 Sep; 29(3):236-241. PubMed ID: 29453600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
    Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG
    Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
    Walts AE; Bomalaski JS; Ines D; Orsulic S
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1363-9. PubMed ID: 25548129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
    Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
    J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
    Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
    Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
    Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
    Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
    Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
    Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
    Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.
    Savaraj N; Wu C; Kuo MT; You M; Wangpaichitr M; Robles C; Spector S; Feun L
    Drug Target Insights; 2007; 2():119-28. PubMed ID: 21901069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.
    Sahu D; Gupta S; Hau AM; Nakashima K; Leivo MZ; Searles SC; Elson P; Bomalaski JS; Casteel DE; Boss GR; Hansel DE
    Am J Pathol; 2017 Jan; 187(1):200-213. PubMed ID: 27979310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
    Delage B; Fennell DA; Nicholson L; McNeish I; Lemoine NR; Crook T; Szlosarek PW
    Int J Cancer; 2010 Jun; 126(12):2762-72. PubMed ID: 20104527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
    Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
    Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.
    Phillips MM; Sheaff MT; Szlosarek PW
    Cancer Res Treat; 2013 Dec; 45(4):251-62. PubMed ID: 24453997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.